Skip to main content
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc — Investor Relations & Filings

Ticker · XFOR ISIN · US0428731097 LEI · 549300R0UFVPXWP86U94 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2019-08-14 Regulatory Filings
Country US United States of America
Listing US XFOR

About X4 Pharmaceuticals, Inc

https://www.x4pharma.com/

X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases of the immune system. The company focuses on diseases resulting from the dysfunction of the CXCR4 pathway, a key signaling pathway for immune cell trafficking. Its lead product, XOLREMDI™ (mavorixafor), is an oral, selective antagonist of the CXCR4 receptor. It is approved for use in patients aged 12 and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) to increase the number of circulating neutrophils and lymphocytes. The company's pipeline includes further investigation of mavorixafor for other chronic neutropenic disorders.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings
2019-08-14 English
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC by X4 Pharmaceuticals, Inc. It registers shares of common stock under an inducement equity incentive plan. The text includes details about the registration fee, incorporation by reference of other SEC filings (10-K, 10-Q, proxy statements, 8-Ks), and legal provisions related to indemnification of directors and officers. Form S-8 is a registration statement used for securities issued under employee benefit plans and is not a financial report, earnings release, or other types of filings listed. It is a capital markets filing related to securities registration for stock-based compensation plans. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is substantial and contains detailed registration information, not just an announcement or reference to a report, so it is not RPA or RNS. Confidence is high due to clear identification of Form S-8 and its purpose.
2019-08-09 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities for public offering. It includes details about the securities to be offered, the registration fee, and the prospectus for the offering. This type of filing is related to capital raising activities and financing, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual registration statement document. Therefore, it fits the category of Capital/Financing Update filings.
2019-08-09 English
8-K
Management Reports Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 9, 2019. It references prior filings including a business combination announcement and an amendment with audited financial statements and pro forma financial information. The key new content in this filing is the inclusion of Management's Discussion and Analysis (MD&A) of Financial Condition and Results of Operations for the year ended December 31, 2018, filed as Exhibit 99.1. The MD&A is a detailed management report explaining financial results and business trends. The document is relatively short (3830 characters) but contains substantive MD&A content, not just an announcement or certification. Therefore, the filing is best classified as a Management Reports (MDA) filing rather than a full Annual Report (10-K) or a simple announcement (RPA).
2019-08-09 English
10-Q
Interim / Quarterly Report Q2 2019
2019-08-07 English
SC 13D/A
Major Shareholding Notification
2019-07-17 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.